UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Cell, 2004-11, Vol.119 (5), p.591-602

2004

Volltextzugriff (PDF)

465 INVITED Challenges in the development of antibody drug conjugates

European journal of cancer supplements, 2008, Vol.6 (12), p.149-149

Lutzker, S

2008

Volltextzugriff (PDF)

Design and Clinical Development of Antibody Drug Conjugates

Annals of oncology, 2013-03, Vol.24, p.i7-i7

Lutzker, S.

2013

Volltextzugriff (PDF)

A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation

Nature medicine, 1996-07, Vol.2 (7), p.804-810

1996

Volltextzugriff (PDF)

PP01.11 Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e14-e15

2023

Volltextzugriff (PDF)

Going performative in education – the artistry of teaching: On the focus of Waldorf education in this issue, based on a personal review

Scenario (Cork), 2022-08, Vol.XVI (1), p.105-112

2022

Volltextzugriff (PDF)

Mainstream ELT and Steiner Education: Exclusivity or complementarity?

Scenario (Cork), 2022-08, Vol.XVI (1), p.89-104

2022

Volltextzugriff (PDF)

P53 tumour suppressor gene and germ cell neoplasia

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 1998-01, Vol.106 (1-6), p.85-89

LUTZKER, STUART G.

1998

Volltextzugriff (PDF)

Use of dendritic cells to immunize against cancers overexpressing p53

Clinical cancer research, 2001, Vol.7 (1), p.2-4

2001

Volltextzugriff (PDF)

A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells

Oncogene, 2001-05, Vol.20 (23), p.2982-2986

2001

Volltextzugriff (PDF)

Secondary genomic rearrangement events in pre‐B cells: VHDJH replacement by a LINE‐1 sequence and directed class switching

The EMBO journal, 1986-12, Vol.5 (12), p.3259-3266

1986

Volltextzugriff (PDF)

Mitogen plus interleukin 4 induction of Cε transcripts in B lymphoid cells

The Journal of experimental medicine, 1988-12, Vol.168 (6), p.2385-2389

1988

Volltextzugriff (PDF)

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53

The Journal of biological chemistry, 2004-08, Vol.279 (35), p.36440-36444

2004

Volltextzugriff (PDF)

Structure and expression of germ line immunoglobulin gamma 2b transcripts

Molecular and Cellular Biology, 1988-04, Vol.8 (4), p.1849-1852

1988

Volltextzugriff (PDF)

Content Rights for Creative Professionals: Copyrights & Trademarks in a Digital Age

2nd Edition, 2013

Volltextzugriff (PDF)

Structure and expression of germ line immunoglobulin heavy-chain epsilon transcripts: interleukin-4 plus lipopolysaccharide-directed switching to C epsilon

Molecular and Cellular Biology, 1990-04, Vol.10 (4), p.1672-1679

1990

Volltextzugriff (PDF)

Apoptosis and cancer chemotherapy

Cancer treatment and research, 1996, Vol.87, p.345

1996

Volltextzugriff (PDF)

Handbook of Child Abuse Research and Treatment

1, 1998

Volltextzugriff (PDF)

A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)—Final report

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.19105-19105

2008

Volltextzugriff (PDF)

A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18150-18150

2007

Volltextzugriff (PDF)

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1042-1042

2007

Volltextzugriff (PDF)

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1029-1029

2008

Volltextzugriff (PDF)

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1028-1028

2008

Volltextzugriff (PDF)

Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies

European journal of cancer (1990), 2009-03, Vol.45 (5), p.741-746

2009

Volltextzugriff (PDF)

P-440 Cell culture based sequenced gemcitabine (G), carboplatin (C)and paclitaxel (P); GCP for advanced stage IV non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S232-S232

2005

Volltextzugriff (PDF)

1 – 25 von 505

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(380)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(503)
Deutsch
(3)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(93)
Social Sciences
(84)
Science & Technology
(82)
Life Sciences & Biomedicine
(78)
Psychology
(73)
Biological And Medical Sciences
(63)
Child Abuse
(54)
Medical Sciences
(53)
Male
(51)
Female
(46)
Psychology. Psychoanalysis. Psychiatry
(45)
Psychopathology. Psychiatry
(43)
Psychology, Clinical
(42)
Child
(40)
Adult
(35)
Family Studies
(29)
Child Neglect
(25)
Child Abuse & Neglect
(24)
Child Maltreatment
(23)
Child, Preschool
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

465 INVITED Challenges in the development of antibody drug conjugates

Design and Clinical Development of Antibody Drug Conjugates

A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation

PP01.11 Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations

Going performative in education – the artistry of teaching: On the focus of Waldorf education in this issue, based on a personal review

Mainstream ELT and Steiner Education: Exclusivity or complementarity?

P53 tumour suppressor gene and germ cell neoplasia

Use of dendritic cells to immunize against cancers overexpressing p53

A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells

Secondary genomic rearrangement events in pre‐B cells: VHDJH replacement by a LINE‐1 sequence and directed class switching

Mitogen plus interleukin 4 induction of Cε transcripts in B lymphoid cells

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53

Structure and expression of germ line immunoglobulin gamma 2b transcripts

Content Rights for Creative Professionals: Copyrights & Trademarks in a Digital Age

Structure and expression of germ line immunoglobulin heavy-chain epsilon transcripts: interleukin-4 plus lipopolysaccharide-directed switching to C epsilon

Apoptosis and cancer chemotherapy

Handbook of Child Abuse Research and Treatment

A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)—Final report

A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)

A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)

A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)

Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies

P-440 Cell culture based sequenced gemcitabine (G), carboplatin (C)and paclitaxel (P); GCP for advanced stage IV non-small cell lung cancer (NSCLC)

Suchergebnisse filtern